Henan Taloph Pharmaceutical Stock Co Ltd - Asset Resilience Ratio

Latest as of June 2025: 0.06%

Henan Taloph Pharmaceutical Stock Co Ltd (600222) has an Asset Resilience Ratio of 0.06% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Henan Taloph Pharmaceutical Stock Co Ltd for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥2.20 Million
≈ $321.94K USD Cash + Short-term Investments

Total Assets

CN¥3.58 Billion
≈ $523.73 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how Henan Taloph Pharmaceutical Stock Co Ltd's Asset Resilience Ratio has changed over time. See Henan Taloph Pharmaceutical Stock Co Ltd shareholders equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Henan Taloph Pharmaceutical Stock Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 600222 market cap.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥2.20 Million 0.06%
Total Liquid Assets CN¥2.20 Million 0.06%

Asset Resilience Insights

  • Limited Liquidity: Henan Taloph Pharmaceutical Stock Co Ltd maintains only 0.06% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Henan Taloph Pharmaceutical Stock Co Ltd Industry Peers by Asset Resilience Ratio

Compare Henan Taloph Pharmaceutical Stock Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
Drug Manufacturers - Specialty & Generic 0.44%
Emcure Pharmaceuticals Ltd
NSE:EMCURE
Drug Manufacturers - Specialty & Generic 1.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Ningbo Menovo Pharm Co Ltd
SHG:603538
Drug Manufacturers - Specialty & Generic 2.69%
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
Drug Manufacturers - Specialty & Generic 20.24%
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
Drug Manufacturers - Specialty & Generic 0.40%

Annual Asset Resilience Ratio for Henan Taloph Pharmaceutical Stock Co Ltd (2014–2024)

The table below shows the annual Asset Resilience Ratio data for Henan Taloph Pharmaceutical Stock Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 2.29% CN¥80.02 Million
≈ $11.71 Million
CN¥3.49 Billion
≈ $510.66 Million
-1.99pp
2023-12-31 4.29% CN¥153.30 Million
≈ $22.43 Million
CN¥3.58 Billion
≈ $523.41 Million
+2.20pp
2022-12-31 2.08% CN¥74.96 Million
≈ $10.97 Million
CN¥3.60 Billion
≈ $526.82 Million
-5.47pp
2021-12-31 7.55% CN¥285.67 Million
≈ $41.80 Million
CN¥3.78 Billion
≈ $553.68 Million
+1.43pp
2020-12-31 6.12% CN¥207.46 Million
≈ $30.36 Million
CN¥3.39 Billion
≈ $495.98 Million
-0.32pp
2019-12-31 6.44% CN¥176.40 Million
≈ $25.81 Million
CN¥2.74 Billion
≈ $400.86 Million
+1.87pp
2018-12-31 4.57% CN¥129.50 Million
≈ $18.95 Million
CN¥2.84 Billion
≈ $414.90 Million
+1.01pp
2017-12-31 3.56% CN¥100.00 Million
≈ $14.63 Million
CN¥2.81 Billion
≈ $410.92 Million
+1.29pp
2015-12-31 2.27% CN¥60.00 Million
≈ $8.78 Million
CN¥2.64 Billion
≈ $386.25 Million
-0.39pp
2014-12-31 2.66% CN¥61.00 Million
≈ $8.93 Million
CN¥2.29 Billion
≈ $335.35 Million
--
pp = percentage points

About Henan Taloph Pharmaceutical Stock Co Ltd

SHG:600222 China Drug Manufacturers - Specialty & Generic
Market Cap
$570.21 Million
CN¥3.90 Billion CNY
Market Cap Rank
#11884 Global
#3649 in China
Share Price
CN¥6.79
Change (1 day)
-0.15%
52-Week Range
CN¥5.17 - CN¥8.58
All Time High
CN¥10.35
About

Henan Taloph Pharmaceutical Stock Co.,Ltd engages in the research, development, and sale of pharmaceutical preparations and Chinese herbal medicines in China. Its principal products include Shuanghuanglian oral liquid series, Shuangjinlian mixture, pediatric Qingrezhike oral liquid, Huoxiangzhengqi mixture, Danshen and Wuzi Yanzong oral liquid, Shengmaiyin, pediatric compound chicken gizzard chew… Read more